Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Study finds vitamin D supplement does not reduce knee osteoarthritis progression

Adding vitamin D as a supplement does not appear to lessen the symptoms, or slow the progression, of knee osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Scientists discover new way to create human blood from adult skin

In an important breakthrough, scientists at McMaster University have discovered how to make human blood from adult human skin. The discovery, published in the prestigious science journal Nature today, could mean that in the foreseeable future people needing blood for surgery, cancer treatment or treatment of other blood conditions like anemia will be able to have blood created from a patch of their own skin to provide transfusions.

7 Nov 2010

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported third quarter 2010 results today.

4 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

First Edition: November 3, 2010

Today's headlines track the GOP's sweeping electoral gains and begin to explore what this power shift might mean for the future of the health law.

3 Nov 2010

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

3 Nov 2010

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.

2 Nov 2010

Mechanism of rogue cell killer discovered

A team of Melbourne and London researchers have shown how a protein called perforin punches holes in, and kills, rogue cells in our bodies. Their discovery of the mechanism of this assassin is published today in the science journal Nature.

1 Nov 2010

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Scientists from the UK and Australia have seen the human immune system's assassin a protein called perforin in action for the first time. The UK team, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Wellcome Trust, is based at Birkbeck College where they used powerful electron microscopes to study the mechanism that perforin uses to punch holes in rogue cells.

1 Nov 2010

Proteins to punch holes in cancer cells to kill them: Study

In a medical breakthrough scientists have found a protein called perforin that kills rogue cells in the human body especially the ones causing cancer. The team comprising of experts from Melbourne and London found that perforin punches holes and kills these cells. The research appeared in the acclaimed journal Nature.

31 Oct 2010

Annual meeting of INFORMS to take place at Austin Convention Center

When 4,000 experts in everything from laws about using your cell phone while driving to using math to decide whether to punt or pass on fourth down come to Austin on November 7, the city will find itself deluged not only by smart people who use math for a living but also problem solvers who tackle America's greatest threats.

30 Oct 2010

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

Systemic amyloidosis patient to receive triple organ transplant

In 2005, then 40-year-old Walt McGuire was playing hockey twice a week, working full-time and chasing his young daughter. Then one day, he noticed after one trip up the stairs to catch her, he couldn't catch his breath. A few days later his legs were swollen. After numerous trips to different doctors, McGuire finally was diagnosed with a rare blood disorder called amyloidosis.

28 Oct 2010

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

New guideline for using ESAs drugs in cancer patients

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

27 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010

Aastrom Biosciences and ATEK Medical enter new strategic partnership

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, and ATEK Medical, a leading medical device manufacturer, today announced the formation of a new strategic partnership in which ATEK Medical will supply key components and technology for use in Aastrom's proprietary cell manufacturing process.

26 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010